RU2170575C1 - Preparation for treatment of animal udder with mastitis, wound, trauma and burn - Google Patents

Abstract

FIELD: veterinary science. SUBSTANCE: method involves treatment of animal udder with mastitis, skin traumas and burns with preparation containing the following components, as measured for a single administration dose, g/ml: benzylpenicillin sodium or potassium salt, 10 000-20 000 IU/ml; streptomycin sulfate, 10 000-20 000 IU/ml; norsulfazol, 0.03-0.04; oil, 0.90-0.91; soft monoglyceride, 0.03; solid monoglyceride 0.03; Preparation is prepared by dispersing antibiotics and norsulfazol powders in oily base (oil with emulsifying agents) in colloid mill up to preparing the homogeneous and stable suspension. Curative administration dose of the preparation is 5-10 ml. After two-fold use of the preparation recovery of animals occurs in 1-5 days of treatment. EFFECT: enhanced effectiveness of preparation. 18 cl, 4 tbl, 5 ex

Description

 The invention relates to agriculture, in particular to veterinary medicine, and can be used to treat mastitis, wounds, injuries and burns of the skin of the udder of animals.

 Mastitis (Mastitis) is an inflammation of the mammary gland that develops as a result of exposure to mechanical, thermal, chemical and biological factors. Mastitis to this day remains one of the diseases that most often affects cows and causes great economic damage. It is registered in almost all countries with developed dairy cattle breeding, affecting from 30 to 50% of the number of cows taking into account subclinical forms of the disease. Damage from this disease includes more than 12 categories of losses, but the most significant decrease in milk productivity and milk quality. Mastitis is a polyetiological disease. However, streptococci, staphylococci, E. coli, mycoplasmas, and fungi are most often isolated from most pathogens. The causative agents of mastitis penetrate the mammary gland in various ways, but the galactogenic pathway plays the main role. By the nature of the inflammation, mastitis happens: serous, catarrhal, fibrinous, purulent, hemorrhagic and specific. With the course of mastitis is acute (up to 10 days), subacute (up to 3 weeks) and chronic (more than 3 weeks). For the prevention and treatment of mastitis, complex therapy is recommended, including organizational-economic and veterinary-economic measures, as well as pathogenetic therapy, physical and medical methods. In the complex of measures to combat mastitis, the main importance is attached to the use of special anti-mastitis drugs that have an antibacterial effect against pathogens of the udder. Currently, domestic and foreign industries produce many different drugs for the treatment of cows with mastitis. They vary in combination of antimicrobial agents, the base (solvent) used, dose and route of administration. Trying to improve the results of antimicrobial substances in mastitis, many scientists recommend administering to animals a complex of antibiotics with sulfonamides, believing that the combined effect of these drugs expands their spectrum of action on microorganisms and prevents the emergence of resistant strains of pathogens. In the treatment of mastitis, complex drugs are mainly used in oil, which are administered intracisternally. But due to the viscosity of the pathological secretion of the mammary gland, they do not always penetrate quickly and deeply into tissues (1).

 Mastaerosol containing penicillin, erythromycin, alcohol, castor oil, propylene glycol -1200 and prednisolone has found widespread use in veterinary practice (2,3).

Known drug "Mastisan-A" for the treatment of mastitis in animals, containing potassium or sodium salt of benzylpenicillin, streptomycin sulfate, sulfadimesin or norsulfazole, or norsulfazole sodium, vegetable or liquid paraffin and emulsifiers as an oil base in the following ratio of ingredients, g / ml dose introduction:
Potassium or sodium salt of benzylpenicillin - 20,000 IU / ml
Streptomycin sulfate - 20,000 IU / ml
Sulfademinisine or norsulfazole or sodium norsulfazole - 0.04
Oil base - up to 1.0.

 The dose is 5.0 ml (4.5).

Known drug "Mastisan-B" for the treatment of mastitis in animals, containing neomycin sulfate, sulfademisine, methyluracil, liquid paraffin and polyglycerol distirate as an oil base in the following ratio of ingredients, g / ml dose of administration:
Neomycin Sulfate - 250 PIECES / ml
Sulfadimezin - 0.0035
Methyluracil - 0.0035
Oil base - up to 1.0 (6.5).

Known drug "Mastisan-E" for the treatment of mastitis in animals, containing erythromycin, sulfadimesin, polyethylsiloxane liquid with an emulsifier as an oil base in the following ratio of ingredients, g / ml dose of administration:
Erythromycin - 11250 IU / ml
Sulfadimezin - 0.04
Oil base - up to 1.0 (7.5).

Known drug "Masticide" for the treatment of cows with mastitis, containing potassium or sodium salt of penicillin, streptomycin sulfate, norsulfazole, sulfadimezin, sunflower or liquid paraffin and emulsifier as an oil base in the following ratio of ingredients, g / ml dose:
Penicillin potassium or sodium salt - 20,000 IU / ml
Streptomycin sulfate - 10,000 units / ml
Norsulfazole - 0.0035
Emulsifier - 0.035
Sunflower or petroleum jelly oil - up to 1.0 (8).

 The known drug "Masticide-2" for the treatment of cattle mastitis contains antibiotics, sulfonamides and vegetable oil, with benzylpenicillin, streptomycin being used as antibiotics, sulfadimesin, norsulfazole from sulfonamides (9, 10).

Known drug for the treatment and prevention of mastitis in cattle, containing the antibiotic hemolycin, lanolin and paraffin oil in the following ratio, wt.%:
Heliomycin - 2.0-4.0
Lanolin - 20.0-40.0
Vaseline oil - up to 100.0 (11).

Known drug for the treatment and prevention of mastitis in cattle, containing the antibiotic apramycin, paraffin oil and lanolin in the following ratio, wt.%:
Apramycin - 2.0-5.0
Lanolin - 20.0-40.0
Vaseline oil - up to 100.0 (12).

Known drug for the treatment and prevention of mastitis in cows, containing the antibiotic tylosintartrate, acetylsalicylic acid, ethyl alcohol, polypropylene glycol-1200 and castor oil in the following ratio of these ingredients, wt.%:
Tylosintartrate - 0.37-1.0
Acetylsalicylic acid - 0.6-1.6
Ethyl alcohol - 15.0-22.0
Polypropylene glycol-1200 - 15.0-22.0
Castor oil - up to 100 (13).

 A common disadvantage of known preparations made in the form of a suspension or an unstable emulsion is the low therapeutic efficacy. This is due to the fact that antibiotics in the aqueous phase quickly lose activity, and sulfonamides precipitate, which changes the concentration of the active substance at the injection site. In addition, suspensions exfoliate during storage, and vegetable oils are oxidized.

Also known drugs for the treatment of mastitis in animals produced by foreign companies:
- a multimast containing penicillin, neomycin, oxytetracycline hydrochloride, prednisolone and a base (Baimida, Ireland);
- a mastic containing penicillin, streptomycin, superseptil in an oil suspension (Medimpex, Hungary);
- Cloxavet M, containing cloxacillin, penicillin, prednisone and a base (Pliva, Croatia);
- fort mastjet containing tetracycline, neomycin, bacitracin, prednisolone and base (Intervet, Holland);
- tototillin containing ampicillin, oxycycline, triglycerides (Bayer AG, Germany);
- synolox LC, containing amoxicillin, clavulonic acid, prednisolone and a base (Pfizer, USA) and others (14, 15, 16, 17, 18, 19).

 The disadvantages characteristic of domestic medicines are also inherent in foreign veterinary medicines.

Closest to the proposed invention in terms of essential features is the drug "Mastisan-A" for the prevention and treatment of mastitis, as well as traumatic injuries of the skin of the udder of animals, containing potassium or sodium salt of benzylpenicillin, streptomycin sulfate, sulfadimesin or norsulfazole, or norsulfazole sodium, vegetable or liquid paraffin and emulsifiers as an oil base in the following ratio of components, g / ml administration dose:
Potassium or sodium salt of benzylpenicillin - 20,000 IU / ml
Streptomycin sulfate - 20,000 IU / ml
Sulfadimezin or norsulfazole or norsulfazole sodium - 0.07
Oil base - up to 1.0
The dose is 5 ml (4.5).

 The disadvantage of the prototype drug is its low therapeutic activity, due to the fact that during storage the emulsion is stratified and the solid particles of antibiotics and sulfonamides contained in the dispersion medium precipitate.

 The objective of the present invention was to develop a drug for the treatment of mastitis, wounds, injuries and burns of the skin of the udder of animals, which has high prophylactic and therapeutic efficacy due to the dispersion of powders of antibiotics and sulfonamide in an oil base with the formation of a stable suspension, the local application of which contributes to a better distribution of active substances in the affected lobes of the udder, a positive effect and a reduction in the treatment time of sick animals.

 The technical result from the use of the invention is to increase the therapeutic efficacy of the proposed drug.

The specified technical result was achieved by the creation of a drug for the treatment of mastitis, wounds, injuries and burns of the skin of the udder of animals, characterized by the following set of signs:
1) the drug for the treatment of mastitis, wounds, injuries and burns of the skin of the udder of animals contains:
2) antibiotics;
3) from antibiotics, potassium or sodium salt of benzylpenicillin;
4) from antibiotics streptomycin sulfate;
5) potassium or sodium salt of benzylpenicillin in the amount of 10000-20000 IU / ml dose of administration;
6) streptomycin sulfate in an amount of 10000-20000 IU / ml of the dose of administration;
7) sulfonamides;
8) from sulfonamides norsulfazole;
9) norsulfazole in an amount of 0.03-0.04 g / ml dose;
10) oil base;
11) oil;
12) emulsifiers;
13) mineral oil from oils;
14) from mineral oils vaccine oil of brand "M";
15) brand C vaccine oil from mineral oils;
16) brand “B” vaccine oil from mineral oils;
17) synthetic oil from oils;
18) PES-2 oil from synthetic oils;
19) PES-3 oil from synthetic oils;
20) MC oil from synthetic oils;
21) vegetable oil from oils;
22) oil in an amount of 0.9-0.91 g / ml dose;
23) as an emulsifier, the monoglyceride is soft in an effective amount;
24) as an emulsifier, solid monoglyceride in an effective amount;
25) mild monoglyceride in an amount of 0.03 g / ml dose;
26) solid monoglyceride in an amount of 0.03 g / ml administration dose.

The present invention includes the following set of essential features that provide a technical result in all cases for which legal protection is sought:
1) the drug for the treatment of mastitis, wounds, injuries and burns of the skin of the udder of animals contains:
2) antibiotics;
3) sulfonamides;
4) oil base;
5) oil;
6) emulsifiers;
7) as an emulsifier soft monoglyceride;
8) soft monoglyceride in an effective amount;
9) as an emulsifier, solid monoglyceride;
10) solid monoglyceride in an effective amount.

The proposed drug is also characterized by other signs expressing specific forms of execution or special conditions for its use:
1) from antibiotics, the drug contains potassium or sodium salt of benzylpenicillin;
2) from antibiotics, the drug contains streptomycin sulfate;
3) the preparation contains potassium or sodium salt of benzylpenicillin in an amount of 10000-20000 UNITS / ml of the dose of administration;
4) the preparation contains streptomycin sulfate in an amount of 10000-20000 IU / ml of the dose of administration:
5) from sulfonamides, the drug contains norsulfazole;
6) the drug contains norsulfazole in an amount of 0.03-0.04 g / ml dose;
7) from oils, the preparation contains mineral oil or synthetic oil, or vegetable oil;
8) from mineral oils, the preparation contains vaccine oil of the brand "M";
9) from mineral oils, the preparation contains vaccine oil of brand "C";
10) from mineral oils, the preparation contains vaccine oil of brand "B";
11) from synthetic oils, the preparation contains PES-2 oil;
12) from synthetic oils, the preparation contains PES-3 oil;
13) from synthetic oils, the preparation contains MC oil;
14) the preparation contains oil in an amount of 0.9-1.0 g / ml dose;
15) the preparation contains mild monoglyceride in an amount of 0.03 g / ml dose;
16) the preparation contains solid monoglyceride in an amount of 0.03 g / ml administration dose.

The signs of the invention, characterizing the proposed drug and coinciding with the signs of the prototype, including the generic concept, reflecting the purpose, are:
1) the drug for the treatment of mastitis, wounds, injuries and burns of the skin of the udder of animals contains:
2) antibiotics;
3) sulfonamides;
4) oil base;
5) oil;
6) emulsifiers.

 Compared with the preparation of the prototype, the essential distinguishing features of the present invention are the signs characterizing the content of the preparation as emulsifiers of soft monoglyceride and solid monoglyceride taken in an effective amount.

The present invention is also characterized by other distinctive features that express specific forms of execution or special conditions for its use:
1) from antibiotics, the drug contains potassium or sodium salt of benzylpenicillin;
2) from antibiotics, the drug contains streptomycin sulfate;
3) the preparation contains potassium or sodium salt of benzylpenicillin in an amount of 10000-20000 UNITS / ml of the dose of administration;
4) the preparation contains streptomycin sulfate in an amount of 10000-20000 IU / ml dose of administration;
5) from sulfonamides, the drug contains norsulfazole;
6) the drug contains norsulfazole in an amount of 0.03-0.04 g / ml dose;
7) from oils, the preparation contains mineral oil or synthetic oil, or vegetable oil;
8) from mineral oils, the preparation contains vaccine oil of the brand "M";
9) from mineral oils, the preparation contains vaccine oil of the brand “C”;
10) from mineral oils, the preparation contains vaccine oil of brand "B";
11) from synthetic oils, the preparation contains PES-2 oil;
12) from synthetic oils, the preparation contains PES-3 oil;
13) from synthetic oils, the preparation contains MC oil;
14) the preparation contains oil in an amount of 0.9-0.91 g / ml dose;
15) the preparation contains mild monoglyceride in an amount of 0.03 g / ml dose;
16) the preparation contains solid monoglyceride in an amount of 0.03 g / ml administration dose.

 The proposed drug has a higher therapeutic efficacy compared with the prototype drug. As a result of the use of the proposed drug, animal recovery is achieved within 1-2 days after daily double use (5 or 10 ml per affected udder) in acute mastitis or traumatic lesions of the skin of the udder.

 The achievement of the technical result from the use of the proposed preparation is explained by the fact that dispersion of the antibiotic powder and norsulfazole in an oil base with monoglycerides made it possible to obtain a kinetically stable suspension that provides a better distribution of bactericidal concentrations of active substances in the affected udder lobes, and the oil base and monoglycerides used in the preparation have an emollient and prolonging effect.

 The selected concentration of monoglycerides ensures the formation of a persistent non-stratifying emulsion, which ensures uniform distribution of the active principle and its prolonged absorption from the injection site.

 In the case of using only one type of monoglyceride or changing their content leads to the separation of the emulsion and a partial loss of therapeutic efficacy of the drug.

 An analysis of the state of the art by the applicant, including a search by patents and scientific and technical sources of information, and identification of sources containing information about analogues of the proposed drug, made it possible to establish that the applicant did not find a source characterized by signs that were identical (identical) to all the essential features of the proposed drug. The definition from the list of identified analogues of the prototype, as the closest in the totality of the features of the analogue, allowed us to establish a set of significant distinctive features in relation to the applicant’s perceived technical result in the proposed preparation set forth in the claims.

 Therefore, the proposed drug meets the condition of patentability "novelty."

 To check the conformity of the proposed drug to the patentability condition "inventive step", the applicant conducted an additional search for known solutions to identify features included in the distinctive part of the independent claim. The search resulted in the following.

Medicines for treating mastitis containing oil-based antibiotics and sulfonamides are known. Information about them is given in the section "prior art" description of the invention to this application. The functions of the oil base can be characterized as follows:
1) in aqueous solutions, antibiotics quickly lose their activity;
2) provides a better distribution of active substances in the affected lobes of the udder and does not cause an adverse reaction of its tissues. It is known to use monoglycerides as emulsifiers and stabilizers of edible fats, cosmetic creams, pharmaceutical ointments, plasticizers and lubricants, components of compositions for sizing paper, fibers, raw materials for the production of soaps and higher carboxylic acids (20, 21, 22).

 It is proposed for the first time to use monoglycerides as emulsifiers to obtain an aggregatively stable oily suspension of powders. In this case, the monoglyceride molecules adsorbed on solid particles form solvate shells around them and turn the suspension into a kinetically stable emulsion. The result is a drug in which the dispersion medium is oil with monoglycerides, and the dispersed phase is solid particles of antibiotics and norsulfazole.

 The search results showed that the proposed solution does not follow explicitly for the specialist from the prior art set forth in the corresponding section of the description (no solutions having features matching the distinguishing features of the present invention have been identified), and the effect of the transformations provided for by the essential features of the proposed invention has not been identified to achieve a technical result.

 Therefore, the drug meets the condition of patentability "inventive step".

 The invention is illustrated by examples of its implementation.

 Example 1

To prepare 100 ml of the drug, use the dispersed phase in the composition:
Potassium or sodium salt of benzylpenicillin - 1,000,000-200,000 units
Streptomycin sulfate - 1,000,000-200,000 units
Norsulfazole - 3.0-4.0 g.

 The powders are mixed and passed through a disk or ball type grinder, subject to aseptic and antiseptic rules.

As a dispersion medium, oils are used:
mineral (vaccine oil "M" (TU 0253-002-00151.911-93), vaccine oil "C" (TU 0253-002-0015.911-93), vaccine oil "B" (TU 38401139-93), medical vaseline oil ( GOST 3164-78) or synthetic (PES-2 and PES-3 oils (GOST 13004-77), MC oil (TU 38401764-89), or vegetable (GOST 1129-93) (23-29) (in the amount of 90- 91 g, and emulsifiers:
soft monoglyceride - 3 g
solid monoglyceride - 3 g.

To obtain a dispersion medium 6 g of monoglycerides are dissolved at a temperature of 80 ^o C in 90 g of oil. The mixture is autoclaved at a temperature of 112 ^o C for 1.5-2 hours. A suspension of antibacterial agents is introduced into the dispersion medium cooled to 30-35 ^o C and passed through a colloid mill (grade IV, Germany) with a working gap of knives 00 for 10 minutes and immediately packaged. One dose (10 ml) of the drug should contain, g / ml dose of administration:
Potassium or sodium salt of benzylpenicillin - 10000-20000 UNITS / ml
Streptomycin sulfate - 10000-20000 PIECES / ml
Norsulfazole - 0.03-0.04
Oil - 0.9-0.91
Soft monoglyceride - 0.03
Solid monoglyceride - 0.03.

In appearance, the drug is a homogeneous oily suspension of a white or white-yellow color of a viscous consistency with a specific smell of oil. At temperatures above 35 ^o C the suspension has a liquid consistency.

 The drug, prepared in mineral, synthetic or vegetable oil, does not have significant differences in the physicochemical characteristics of the suspension and its antibacterial properties.

The drug completely retains its original properties and does not delaminate for 18-24 months of storage at room temperature 20-25 ^o C.

 The drug is used to treat all forms of mastitis, as well as wounds, injuries and burns of the skin of the udder of animals.

Before the introduction of the drug, milk is dispensed from the diseased quarter of the udder and the suspension is heated to 30-35 ^° C. in the nipple cistern of the diseased quarter of the udder.

 In the treatment of mastitis, the drug is administered 2 times a day at a dose of 5-10 ml, and in the treatment of traumatic injuries and burns of the skin of the udder, the drug is applied in a thin layer on the affected surface.

 During the treatment period and within 6 days after the last administration of the drug, milk from the affected fourth udder is dispensed into a separate bowl and disposed of, and from the rest used for animal feed after boiling.

 Example 2

Tests of the proposed drug containing, g / ml dose of administration:
Benzylpenicillin potassium or sodium salt - 10,000 units / ml
Streptomycin sulfate - 10,000 units / ml
Norsulfazole - 0.03
Oil - 0.91
Soft monoglyceride - 0.03
Solid monoglyceride - 0.03.

 This drug is prepared as described in example 1.

 For a comparative assessment of the therapeutic effectiveness of the proposed drug and the prototype drug in the acute course of mastitis, two groups of cows were formed (29-32 heads each), patients with the indicated form of mastitis. Animals were selected for clinical signs and test milk donation. The therapeutic effect was also determined by clinical research methods and test donation of milk and / or secretion during treatment and 2-4 weeks after treatment. Doses and the frequency of administration of the proposed drug and the prototype drug both during lactation and in the dry period were determined according to the relevant instructions for the drugs.

An experimental group of cows with subclinical leaking mastitis, as well as with serous, catarrhal and hemorrhagic mastitis, was administered 2 times a day in a dose of 10 ml into the tank of each quarter of the udder. Before the introduction of the drug, milk was dispensed, and the nipple was disinfected. Before use, the drug is heated to 30-35 ^o C and thoroughly shaken until a homogeneous suspension. After the administration of the drug, a light massage of the nipple of the udder was performed from the bottom up. As a rule, already on the second day, clinical improvement of sick cows was noted, and recovery occurred on the 2nd-3rd day. Side effects were not observed. When using the drug to treat mastitis in 122 cows, the therapeutic efficacy was 93.33-96.88%. The control group of cows for the treatment of similar forms of mastitis used the prototype drug, the recovery from which occurred on 2-5 days with therapeutic efficacy of 90.0-93.55%.

 The research results are presented in table. 1.

 Example 3

Tests of the proposed drug containing, g / ml dose of administration:
Potassium or sodium salt of benzylpenicillin - 15000 IU / ml
Streptomycin sulfate - 15,000 units / ml
Norsulfazole - 0.035
Oil - 0,905
Soft monoglyceride - 0.03
Solid monoglyceride - 0.03.

 This drug is prepared as described in example 1.

A comparative assessment of the therapeutic effectiveness of this formulation of the proposed drug and the prototype drug was carried out in the treatment of cows fibrinous and purulent mastitis. The studies were carried out as described in example 2. In this case, cows often observed purulent-fibrinous inflammation of the udder, and mastitis was differentiated by detecting fibrin or a large number of purulent bodies in milk. In the presence of flakes and pus in secret, a soda-salt solution was previously introduced into the udder, and after 20-30 minutes the injected solution was crushed and the proposed preparation was administered. The therapeutic efficacy of the proposed drug was 70.0-83.33% and the prototype drug - 60.0 - 66.7%. (table 2)
Example 4

Tests of the proposed drug containing, g / ml dose of administration:
Potassium or sodium salt of benzylpenicillin - 20,000 units
Streptomycin sulfate - 20,000 units
Norsulfazole - 0.04
Oil - 0.90
Soft monoglyceride - 0.03
Solid monoglyceride - 0.03.

 This drug is prepared as described in example 1.

 A comparative assessment of the therapeutic effectiveness of this formulation of the proposed drug and the prototype drug was carried out on cows with superficial wounds and bruises of the udder. It was found that the proposed drug provides healing within 1-4 days with 1-2-fold use, and the prototype drug for 2-5 days with 2-4-fold use. In addition, the proposed drug was effective in case of skin burns of the udder by the rays of the sun and dermatitis of the udder. After 1-4-fold administration, all 40 animals recovered.

 The test results are given in table. 3.

 Example 5

 A comparison of the therapeutic efficacy of the proposed drug and the prototype drug was carried out under the conditions of wide industrial experience in various farms of the Vladimir region. The test results are summarized in table. 4.

Thus, the above information indicates the fulfillment when using the invention of the following set of conditions:
- the proposed drug, embodying the invention, is intended for use in veterinary medicine;
- for the proposed invention in the form described in the independent claim, the possibility of its implementation using the means and methods described in the application or known prior to the priority date has been confirmed;
- when using the proposed drug, a technical result is achieved, provided by the objective of the invention: a preparation is obtained, characterized in that it has higher therapeutic efficacy compared to the prototype drug, due to the stability of the suspension of antibiotics and norsulfazole in an oil base, does not irritate the udder tissue and has antiseptic effect, and also accelerates the regeneration of damaged tissue.

Sources of information
1. Studentsov A. P., Shipilov V. S. et al. Veterinary obstetrics, gynecology and biotechnology of reproduction. M., Kolos, 1999, 357-369.

 2. Veterinary drugs. Kiev, Harvest, 1972, 115 p.

 3. Auth. testimonial. USSR N 454910, A 61 K 31/42, 1972

 4. Instruction for the use of mastisan-A for the treatment of cows with mastitis. Approved GUV Ministry of Agriculture of the USSR 10.25.82 g. (Prototype).

 5. Ivashura A.I. The system of measures to combat mastitis of cows. M., Rosagropromizdat, 1991, 168-201.

 6. Manual on the use of mastisan-B for the treatment of cows with mastitis. Approved GUV Ministry of Agriculture of the USSR 10.22.82.

 7. Instruction for the use of mastisan-E for the treatment of cows with mastitis. Approved GUV Ministry of Agriculture of the USSR 10.22.82 g.

 8. Manual on the use of masticide for the treatment of cows with mastitis. Approved GUV Ministry of Agriculture of the USSR 10/14/81

 9. Chervyakov D.K. et al. Medicines in veterinary medicine. Directory. M., Kolos, 1977, ed. 2, 434-444.

 10. Manual on the use of masticide-2. Approved GUV Ministry of Agriculture of the USSR 06/18/84.

11. Pat. RF N 2058781, IPC ⁶ A 61 K 35/74, 31/00, 04/27/96

12. Pat. RF N 2058782; IPC ⁶ A 61 K 35/74, 31/00, 04/27/96

13. Pat. RF N 1684981, IPC ⁶ A 61 K 31/00, 02.27.95

 14. Index of veterinary drugs. Yndustrial Irading Laintex veterani, S.A. Industrial vetermaria, S.A. Invesa.

 15. Medicines and premixes. For veterinary use. Budapest, Medimpex, 35-36, 80-82.

 16. Directory of veterinary drugs. Minsk, 1996, 66-71.

 17. Klenova I.F., Ilyukhina I.N. et al. Foreign veterinary preparations in Russia. 1999-2000. Directory. M., Evers Company, 1999, 185-191.

 18. Catalog of veterinary drugs. Bayer, 16-18.

 19. Catalog of veterinary products. Zagreb, Republic of Croatia. JSC "Pliva", 52-55.

 20. TU 10-04-02-42-89 "Distilled monoglycerides."

 21. TU 10-04-02-04-86 "Soft monoglyceride."

 22. Chemical encyclopedia. M., ed. "Sov. Encyclopedia", 1989, v. 1, 584-585.

 23. TU 0253-002-00151.911-93.

 24. TU 0253-002-0015.911-93.

 25. TU 38401139-93.

 26. GOST 3164-78.

 27. GOST 13004-77.

 28. TU 38401764-89.

 29. GOST 1129-93.

Claims (18)

 1. The drug for the treatment of mastitis, wounds, injuries and burns of the skin of the udder of animals, containing antibiotic, sulfonamides, oil and emulsifiers as an oil base, characterized in that as emulsifiers it contains soft monoglyceride and solid monoglyceride, taken in an effective amount.  2. The drug according to claim 1, characterized in that the antibiotic contains potassium or sodium salt of benzylpenicillin.  3. The drug according to claim 1, characterized in that the antibiotic contains streptomycin sulfate.  4. The drug according to claim 1 or 2, characterized in that it contains a potassium or sodium salt of benzylpenicillin in an amount of 10,000 - 20,000 IU / ml dose of administration.  5. The drug according to p. 1 or 3, characterized in that it contains streptomycin sulfate in an amount of 10,000 - 20,000 IU / ml dose of administration.  6. The drug according to claim 1, characterized in that the sulfonamide contains norsulfazole.  7. The drug according to claim 1 or 6, characterized in that it contains norsulfazole in an amount of 0.03 to 0.04 g / ml dose of administration.  8. The drug according to claim 1, characterized in that the oil contains mineral oil, or synthetic oil, or vegetable oil.  9. The drug according to claim 1 or 8, characterized in that the mineral oil contains vaccine oil brand M.  10. The drug according to claim 1 or 8, characterized in that the mineral oil contains vaccine oil brand C.  11. The drug according to claim 1 or 8, characterized in that the mineral oil contains vaccine brand B.  12. The drug according to claim 1 or 8, characterized in that the synthetic oil contains PES-2 oil.  13. The drug according to claim 1 or 8, characterized in that the synthetic oil contains PES-3 oil.  14. The drug according to claim 1 or 8, characterized in that the synthetic oil contains MC oil.  15. The drug according to any one of claims 1, 8 to 14, characterized in that it contains oil in an amount of 0.90 - 0.91 g / ml dose of administration.  16. The drug according to claim 1, characterized in that it contains soft monoglyceride in an amount of 0.03 g / ml dose of administration.  17. The drug according to claim 1, characterized in that it contains solid monoglyceride in an amount of 0.03 g / ml dose of administration. 18. The drug according to any one of claims 1 to 17, characterized in that it contains potassium or sodium salt of benzylpenicillin, streptomycin sulfate, norsulfazole, oil, soft monoglyceride and solid monoglyceride in the following ratio, g / ml dose:
Benzylpenicillin potassium or sodium salt - 10,000 - 20,000 IU / ml
Streptomycin sulfate - 10,000 - 20,000 IU / ml
Norsulfazole - 0.03 - 0.04
Oil - 0.90 - 0.91
Soft monoglyceride - 0.03
Solid monoglyceride - 0.03E

Images